Joshua Bleharski - 30 Jan 2026 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Feb 2026, 20:05:22 UTC
Prior SEC filing
27 Jun 2025
Next SEC filing
23 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua Bleharski

Key filing fact

Joshua Bleharski filed Form 4 for IDEAYA Biosciences, Inc. (IDYA) on 02 Feb 2026.

Key facts

  • This page summarizes Joshua Bleharski's Form 4 filing for IDEAYA Biosciences, Inc. (IDYA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Feb 2026, 20:05.

Change

  • Previous filing in this sequence was filed on 27 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002075052 Primary reporting owner

Bleharski Joshua

Relationship
Chief Financial Officer
Address
C/O IDEAYA BIOSCIENCES, INC., 5000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO
Signature
/s/ Joshua Bleharski
Signature date
02 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDYA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+170,000
Change %
Price
$0.000000
Shares after
170,000
Date
30 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
170,000
Exercise price
$32.19
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .